<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04104685</url>
  </required_header>
  <id_info>
    <org_study_id>FX2016-40</org_study_id>
    <nct_id>NCT04104685</nct_id>
  </id_info>
  <brief_title>A Study to Compare FCD105 Foam to Minocycline 3% Foam, Adapalene 0.3% Foam and Vehicle Foam.</brief_title>
  <official_title>A Prospective, Multicenter, Randomized, Double-Blind, Vehicle-Controlled Phase 2 Study to Evaluate the Safety and Efficacy of a Combination of 3% Minocycline and 0.3% Adapalene Topical Foam Formulation for the Treatment of Moderate-to-Severe Acne (Study FX2016 40)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Foamix Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Foamix Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study comparing FCD105 to 3% minocycline foam, 0.3% adapalene foam and vehicle foam in
      patients ≥ 12 years old for the treatment of moderate-to-severe acne.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 18, 2019</start_date>
  <completion_date type="Actual">March 3, 2020</completion_date>
  <primary_completion_date type="Actual">February 28, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absolute change from Baseline in inflammatory lesion counts at week 12</measure>
    <time_frame>12 weeks</time_frame>
    <description>Statistical superiority of FCD105 vs. vehicle in the absolute change from Baseline in inflammatory lesion counts at Visit 4 (Week12/End of Treatment)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Absolute change from Baseline in non-inflammatory lesion counts at week 12</measure>
    <time_frame>12 weeks</time_frame>
    <description>Statistical superiority of FCD105 vs. vehicle in the absolute change from Baseline in non-inflammatory lesion counts at Visit 4 (Week12/End of Treatment)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Investigator's Global Assessment (IGA) Treatment Success at Week 12</measure>
    <time_frame>12 weeks</time_frame>
    <description>Statistical superiority of FCD105 vs. vehicle in in IGA Treatment Susccess at Visit 4 (Week 12/End of Treatment), where success is defined as an IGA score of 0 or 1, and at least a 2-grade improvement (decrease) from Baseline.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">446</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>FCD105 Foam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FCD105 Foam</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3% Minocycline Foam</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>3% Minocycline Foam</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.3% Adapalene Foam</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.3% Adapalene Foam</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle Foam</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle Foam</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>FCD105</intervention_name>
    <description>Experimental combination</description>
    <arm_group_label>FCD105 Foam</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>3% Minocycline Foam</intervention_name>
    <description>Active Comparator</description>
    <arm_group_label>3% Minocycline Foam</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.3% Adapalene Foam</intervention_name>
    <description>Active Comparator</description>
    <arm_group_label>0.3% Adapalene Foam</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Vehicle Foam</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Vehicle Foam</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Has facial acne vulgaris with all of the following:

               1. 20 to 50 inflammatory lesions (papules and/or pustules) on the face.

               2. 25 to 100 non-inflammatory lesions (open and closed comedones) on the face.

               3. IGA score of moderate (3) to severe (4).

          2. No more than two active nodules on the face.

          3. Willing to use only the supplied non-medicated cleanser and to refrain from use of any
             other acne medication, medicated cleanser, excessive sun exposure, and tanning booths
             for the duration of the study

        Exclusion Criteria:

          1. Female who is pregnant or lactating, or is planning a pregnancy during the study.

          2. Acne conglobata, acne fulminans, secondary acne (chloracne, drug-induced acne), or any
             dermatological condition of the face that could interfere with the clinical
             evaluations.

          3. Facial hair (eg, beard, mustache, etc.) that could interfere with the clinical
             evaluations.

          4. Sunburn on the face.

          5. Severe systemic disease as assessed by the Investigator that might interfere with the
             conduct of the study or the interpretation of the results.

          6. Subjects who have a documented history of any of the following:

               1. Allergy to tetracycline-class antibiotics or to any ingredient in the study drug.

               2. Pseudomembranous colitis or antibiotic-associated colitis.

               3. Hepatitis or clinically significant liver damage or clinically significant renal
                  impairment.

               4. Known or suspected premalignant or malignant disease (excluding successfully
                  treated skin cancers).

          7. Subjects who have used the following medications:

             Within 1 week prior to randomization:

               -  Medicated facial cleansers on the face.

               -  Topical acne treatments on the face (other than those listed below).

             Within 4 weeks prior to randomization:

               -  Topical retinoids on the face.

               -  Topical anti-inflammatories and/or corticosteroids on the face.

               -  Topical corticosteroids on body areas other than the face for more than 15
                  consecutive days and on more than 10% of the body surface area. In body folds,
                  such as axillary and inguinal regions, only mild topical steroids are allowed for
                  short term use (≤15 consecutive days).

               -  Systemic antibiotics.

               -  Systemic acne treatments.

             Within 12 weeks prior to randomization:

               -  Systemic retinoids.

               -  Systemic corticosteroids (Note: Intranasal and inhaled corticosteroids may be
                  used throughout the study if the subject is on a stable dose).

          8. Use of sauna during the 2 weeks prior to randomization.

          9. Epilation of the face within 2 weeks prior to randomization.

         10. Folliculitis on the face.

         11. Documented history of depression that is not, in the opinion of the Investigator,
             currently adequately controlled with medication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Foamix Institution #134</name>
      <address>
        <city>Bryant</city>
        <state>Arkansas</state>
        <zip>72022</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Foamix Institution #121</name>
      <address>
        <city>Rogers</city>
        <state>Arkansas</state>
        <zip>72758</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Foamix Institution #106</name>
      <address>
        <city>Encino</city>
        <state>California</state>
        <zip>91436</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Foamix Institution #103</name>
      <address>
        <city>Fremont</city>
        <state>California</state>
        <zip>94538</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Foamix Institution #122</name>
      <address>
        <city>Huntington Beach</city>
        <state>California</state>
        <zip>92647</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Foamix Institution #109</name>
      <address>
        <city>Manhattan Beach</city>
        <state>California</state>
        <zip>90266</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Foamix Institution #132</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Foamix Institution #107</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Foamix Institution #127</name>
      <address>
        <city>Lake City</city>
        <state>Florida</state>
        <zip>32055</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Foamix Institution #135</name>
      <address>
        <city>Miami Beach</city>
        <state>Florida</state>
        <zip>33162</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Foamix Institution #101</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33126</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Foamix Institution #118</name>
      <address>
        <city>Sanford</city>
        <state>Florida</state>
        <zip>32771</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Foamix Institution #120</name>
      <address>
        <city>Sunrise</city>
        <state>Florida</state>
        <zip>33351</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Foamix Institution #128</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Foamix Institution #130</name>
      <address>
        <city>New Albany</city>
        <state>Indiana</state>
        <zip>47150</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Foamix Institution #116</name>
      <address>
        <city>Plainfield</city>
        <state>Indiana</state>
        <zip>46168</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Foamix Institution #123</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40241</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Foamix Institution #126</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Foamix Institution #124</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Foamix Institution #136</name>
      <address>
        <city>Watertown</city>
        <state>Massachusetts</state>
        <zip>02472</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Foamix Institution #114</name>
      <address>
        <city>Clinton Township</city>
        <state>Michigan</state>
        <zip>48038</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Foamix Institution #111</name>
      <address>
        <city>Fridley</city>
        <state>Minnesota</state>
        <zip>55432</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Foamix Institution #102</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89148</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Foamix Institution #115</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10022</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Foamix Institution #108</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11790</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Foamix Institution #104</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Foamix Institution #133</name>
      <address>
        <city>Gresham</city>
        <state>Oregon</state>
        <zip>97030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Foamix Institution #125</name>
      <address>
        <city>Johnston</city>
        <state>Rhode Island</state>
        <zip>02919</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Foamix Institution #119</name>
      <address>
        <city>Mount Pleasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Foamix Institution #110</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Foamix Institution #117</name>
      <address>
        <city>College Station</city>
        <state>Texas</state>
        <zip>77845</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Foamix Institution #112</name>
      <address>
        <city>Pflugerville</city>
        <state>Texas</state>
        <zip>78660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Foamix Institution #105</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Foamix Institution #131</name>
      <address>
        <city>Layton</city>
        <state>Utah</state>
        <zip>84041</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Foamix Institution #113</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>September 24, 2019</study_first_submitted>
  <study_first_submitted_qc>September 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 26, 2019</study_first_posted>
  <last_update_submitted>July 27, 2020</last_update_submitted>
  <last_update_submitted_qc>July 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Minocycline</mesh_term>
    <mesh_term>Adapalene</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

